

## Nanofat: A therapeutic paradigm in regenerative medicine

Madhan Jeyaraman, Sathish Muthu, Shilpa Sharma, Charan Ganta, Rajni Ranjan, Saurabh Kumar Jha

**ORCID number:** Madhan Jeyaraman 0000-0002-9045-9493; Sathish Muthu 0000-0002-7143-4354; Shilpa Sharma 0000-0001-8695-8372; Charan Ganta 0000-0002-9294-3238; Rajni Ranjan 0000-0003-2324-6970; Saurabh Kumar Jha 0000-0002-7437-0755.

**Author contributions:** Jeyaraman M and Muthu S wrote the paper; Sharma S, Ganta C, Ranjan R, and Jha KS performed the data collection.

**Conflict-of-interest statement:** All authors have no conflicts of interest to disclose.

**Country/Territory of origin:** India

**Specialty type:** Research and experimental medicine

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review report's scientific quality classification**

Grade A (Excellent): 0  
Grade B (Very good): B  
Grade C (Good): C  
Grade D (Fair): 0  
Grade E (Poor): 0

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0)

**Madhan Jeyaraman, Sathish Muthu, Saurabh Kumar Jha,** Department of Biotechnology, School of Engineering and Technology, Sharda University, Greater Noida 201306, Uttar Pradesh, India

**Madhan Jeyaraman, Rajni Ranjan,** Department of Orthopaedics, School of Medical Sciences and Research, Sharda University, Greater Noida 201306, Uttar Pradesh, India

**Madhan Jeyaraman, Sathish Muthu, Shilpa Sharma, Charan Ganta,** Indian Stem Cell Study Group, Lucknow 226010, Uttar Pradesh, India

**Sathish Muthu,** Department of Orthopaedics, Government Medical College and Hospital, Dindigul 624001, Tamil Nadu, India

**Shilpa Sharma,** Department of Pediatric Surgery, All India Institute of Medical Sciences, New Delhi 110029, New Delhi, India

**Charan Ganta,** Department of Stem Cells and Regenerative Medicine, Kansas State University, Manhattan, United States 10002, United States

**Corresponding author:** Sathish Muthu, MS, Research Fellow, Department of Biotechnology, School of Engineering and Technology, Sharda University, Knowledge Park III, Greater Noida 201306, Uttar Pradesh, India. [drsathishmuthu@gmail.com](mailto:drsathishmuthu@gmail.com)

### Abstract

Adipose tissue is a compact and well-organized tissue containing a heterogeneous cellular population of progenitor cells, including mesenchymal stromal cells. Due to its availability and accessibility, adipose tissue is considered a "stem cell depot." Adipose tissue products possess anti-inflammatory, anti-fibrotic, anti-apoptotic, and immunomodulatory effects. Nanofat, being a compact bundle of stem cells with regenerative and tissue remodeling potential, has potential in translational and regenerative medicine. Considering the wide range of applicability of its reconstructive and regenerative potential, the applications of nanofat can be used in various disciplines. Nanofat behaves on the line of adipose tissue-derived mesenchymal stromal cells. At the site of injury, these stromal cells initiate a site-specific reparative response comprised of remodeling of the extracellular matrix, enhanced and sustained angiogenesis, and immune system modulation. These properties of stromal cells provide a platform for the usage of regenerative medicine principles in curbing various diseases. Details about nanofat, including various preparation methods, characterization, delivery methods, evidence on practical applications, and ethical concerns are included in this review. However, appropriate guidelines and preparation protocols for its

license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Received:** March 30, 2021

**Peer-review started:** March 30, 2021

**First decision:** May 12, 2021

**Revised:** May 15, 2021

**Accepted:** October 27, 2021

**Article in press:** October 27, 2021

**Published online:** November 26, 2021

**P-Reviewer:** Casado-Diaz A, Yuan FL

**S-Editor:** Ma YJ

**L-Editor:** Wang TQ

**P-Editor:** Ma YJ



optimal use in a wide range of clinical applications have yet to be standardized.

**Key Words:** Adipose tissue; Nanofat; Stem cells; Regenerative medicine; Adipose stem cells

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

**Core Tip:** Nanofat, being a compact bundle of stem cells with regenerative and tissue remodeling potential, has greater application in translational and regenerative medicine. Nanofat behaves on the line of adipose tissue-derived mesenchymal stromal cells. Considering the reconstructive and regenerative potential, the applications of nanofat can be extrapolated to various medical disciplines such as orthopedics and sports medicine, plastic surgery, and dermatology.

**Citation:** Jeyaraman M, Muthu S, Sharma S, Ganta C, Ranjan R, Jha SK. Nanofat: A therapeutic paradigm in regenerative medicine. *World J Stem Cells* 2021; 13(11): 1733-1746

**URL:** <https://www.wjgnet.com/1948-0210/full/v13/i11/1733.htm>

**DOI:** <https://dx.doi.org/10.4252/wjsc.v13.i11.1733>


## INTRODUCTION

Regenerative medicine encompasses a wide range of approaches, including the use of biologics, stem cell therapy, tissue engineering, cellular reprogramming, and gene therapy to curb various diseases[1,2]. These approaches gave a new dimension to “translational medicine” where the local milieu of the diseased tissue or organs was modulated into a regenerative environment to aid in the healing process[3,4]. Among various available regenerative approaches, stem cell therapy has gained significance. Due to its abundance, availability, and accessibility, the use of adipose tissue and its by-products has sharply increased among varied medical specialties and researchers [5-7].

Adipose tissue biology is complex due to the presence of a heterogeneous cellular population structured in a compact and well-organized manner[8,9]. With the presence of mesenchymal stromal cells as progenitor cells within the organizational structure (Figure 1), the adipose tissue is considered a “stem cell depot”[10]. Compared to embryonic stem cells, adipose stem cells (ASCs) have several advantages: Accessibility, harvesting potential, extraction by a non-terminal procedure, and fewer ethical controversies[11]. Adipose tissue extracts contain various pockets of growth factors, cytokines, adipokines, and transcriptional factors which altogether form secretomes. These acellular secretomes possess more biological activity than whole adipocytes[12]. The products of adipose tissues include microfat, nanofat, microvascular fragments (MVs), the stromal vascular fraction (SVF), adipose-derived stem cells (ASCs), secretomes, and exosomes, which are obtained by minimal or more than minimal manipulation as per the US-FDA guidelines[13].

Utilizing the paracrine effects of the ASCs, the progenitors at the site of interest are stimulated to evoke a clinical response. Upon the addition of peptides, specific growth factors, and cytokines to help in the transfer of secretome molecules containing mRNA and signaling factors to the site of action, their regenerative potential is exponentially increased[14,15].

Out of all the adipose tissue-derived products, researchers are more interested in nanofat and stromal vascular fraction in clinical practices and research since their preparation involves concentration techniques which result in an increased quantity of ASCs[16,17]. Nanofat is one of the richest sources of adipose-derived stem cells and other progenitor cells[16,18-20]. The product “nanofat” is highly attractive in terms of compact pockets of stem cells and biological peptides[16]. There is evidence of the regenerative and tissue remodeling potential of nanofat in dermatological disorders such as scars, wrinkles, pigmentation, chronic wounds, small joints, and certain ligament-tendon targets[21]. Hence, nanofat is a potential adipose tissue product in translational and regenerative medicine.



**Figure 1 Organisational structure of adipose tissue.** MSCs: Mesenchymal stem cells.


## NANOFAT

In 2013, Tonnard *et al*[16] developed an injectable byproduct of adipose tissue called “nanofat”, which was obtained by emulsification and filtration of the lipoaspirates[22-24]. The mechanical disintegration of adipose tissue is to reduce the particle size and to obtain an injectable product[25]. Such adipose-derived particles called nanofat render stromal cell populations to retain vasculature and naïve cellular matrix[26]. Nanofat is an ultra-purified adipose tissue-derived product that is devoid of mature adipocytes but contains CD34+ rich ASCs, microvascular fragments [fragments of arterioles, venules, and capillaries as they are identified by immunohistochemical staining for CD31 and  $\alpha$ -SMA], growth factors [vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), hepatocyte growth factor (HGF), transforming growth factor-beta (TGF- $\beta$ ), basic fibroblast growth factor (bFGF), insulin-like growth factor 1 (IGF-1), and granulocyte-macrophage colony-stimulating factor (GM-CSF)], biological peptides [lipoxins, resolvins, protectins, neurotrophic factors, angiogenin, matrix metalloproteinase 9, leukemia inhibitory factor, and macrophage migration inhibitory factor], and cytokines [BMP-2 and -4, IL-1RA, -4, -8, -10, -11, and -13] as shown in Figure 2[16,23]. It is a liquefied, autologous injectable product with the property of biological integration with adjacent cells and tissues due to its homogenous consistency. The size of nanofat components is approximately 400 to 600  $\mu$ m[27].


Nanofat behaves on the line of adipose tissue-derived mesenchymal stromal cells [28]. At the site of injury, these stromal cells initiate a site-specific reparative response comprised of remodeling of extracellular matrix (ECM), enhanced and sustained angiogenesis, immune system modulation, and cellular turnover[28]. These properties of stromal cells provide a platform for the usage of cellular therapy in various diseases. In 2016, Tamburino *et al* observed the better chances of cellular engraftment of nanofat in various diseases with better functional outcomes[29]. No observation of volume loss, contour irregularities, and liponecrosis was made by grafting nanofat.

## ISOLATION OF NANOFAT

In 2013, Tonnard described a preparation protocol (Figure 3) for harvesting nanofat [16]. After the infiltration of modified Klein solution (lidocaine 800 mg/L and adrenaline 1:1000000) in the lower abdomen, adipose tissue harvesting was performed. To obtain “nanofat”, the adipose tissue should be harvested with a multiport 3 mm cannula with sharp side holes of 1 mm in diameter. Then the harvested adipose tissue is rinsed with normal saline, followed by filtration through a sterile nylon cloth (0.5-mm pore size) mounted over a sterile canister. Mechanical emulsification of adipose



**Figure 2 Molecular composition of nanofat.** VEGF: Vascular endothelial growth factor; PDGF: Platelet-derived growth factor; HGF: Hepatocyte growth factor; TGF-β: Transforming growth factor-beta; bFGF: Basic fibroblast growth factor; IGF-1: Insulin-like growth factor-1; GM-CSF: Granulocyte macrophage colony stimulating factor.



**Figure 3 Schematic representation of nanofat preparation.**

tissue is done by passing the adipose tissue between two syringes connected by a Luer-Lock connector for a minimum of 30 passages, where the size of the adipose tissue is stepped down with every passage and finally converted into an emulsion. The emulsified adipose tissue appears whitish. The emulsified fatty liquid was again filtered over the sterile nylon cloth and the effluent was collected in a sterile container which is named “nanofat” [16]. Nanofat preparation reduces the processing time, cost, and regulatory constraints compared to the enzymatic digestion of the adipose tissue [30,31].

## CHARACTERIZATION OF NANOFAT

Nanofat has gained significant importance in biocellular regenerative medicine[21]. The characterization of nanofat components is based on cellular composition, stromal cell concentrations, and total nuclear counts after membrane lysis. Nanofat is the product of volumetric reduction of mature adipocytes by 95% and contains a concentrated and compact volume of a heterogeneous group of cells equivalent to SVF[21, 32]. However, nanofat may be a superior cell source compared to SVF. Sesé *et al*[26] estimated the total cellular load in the mechanically prepared nanofat to 6.63 million cells/g lipoaspirates whereas in enzymatically disintegrated SVF it was 0.68 million cells/g lipoaspirates. The nucleated cellular count in nanofat was 70% and in SVF was 7.3%. The cellular burden in nanofat contains the stromal cellular population which was equivalent to the lipoaspirate[26]. The low yield of cell counts in SVF was shown to be due to inefficient enzymatic digestion and the vast majority of the cells remained within the extracellular matrix[26].

Nanofat provides a higher concentration of bioactive micromolecules at the target or recipient site, which acts as a bridge to enhance the site-secreted chemotactic agents [26]. The cellular components present in nanofat are multi- and pluripotent and have the potential to differentiate into various cell lineages such as adipose tissue or connective tissue. The extracellular matrix present in nanofat likely caters to the cellular components to sustain the survival of progenitor cells in its composition. Hence, nanofat can be extrapolated for pre-clinical and translational research in tissue engineering[33]. Various pre-clinical and clinical experiments have shown that nanofat grafting helped in angiogenesis, immunomodulation, enhancing collagen deposition, and preventing fibrosis[34,35].

The theories of adipocyte survival after fat grafting include the “graft survival theory” (some transplanted viable adipocytes survive and remain alive for a longer period) and “fat regeneration theory” (under ischaemic conditions, adipose-derived progenitor cells get activated and undergo regeneration)[36,37]. Zheng *et al*[38] demonstrated that fat extract co-transplantation with nanofat enhances fat integrity, survival, and activation of more adipocyte precursors with a higher number of CD31 positive blood vessels, and more Ki67 positive proliferating cells. Under ischaemic conditions, nanofat co-transplantation with fat extract demonstrated proangiogenic and anti-apoptotic effects with multi-differentiation potential[38].

## CELLULAR AND MOLECULAR CHARACTERISTICS OF NANOFAT

The components of nanofat are the derivatives from adipose tissue; hence, nanofat behaves on the line of adipose tissue-derived mesenchymal stem cells (MSCs) at the cellular and molecular levels. Nanofat contains the lowest number of SVF cells. Hence, nanofat is considered the poorest form of SVF. Mohamed-Ahmed *et al* exhibited higher expression of CD34 and CD49d in ASCs; they also showed that CD34 expression helps in long-term MSC proliferation[39]. ASCs express Runx-1 and ALP after 14 d of passage, which resulted in the extended proliferation, maturation, and differentiation of AD-MSCs. The osteogenic capacity of AD-MSCs was induced by mechanical stimulation of culture along with the addition of vitamin D3, PDGF, and BMP-2[40,41]. ASCs activate adipogenesis by induction of adiponectin, leptin, LPL, perilipin, and fatty acid-binding protein-1 through PPAR- $\gamma$  and increased lipid vesicle formation compared to BM-MSCs[42]. The decreased potential for ASC-based chondrogenesis was due to the decreased expression of TGF- $\beta$ -R1 and BMP-2 and -4 [43,44]. The chondrogenic activity of ASCs is identified by the expression of types 2 and 10 collagen, biglycan, aggrecan, and decorin genes in the differentiated cells[45]. ASCs possess a higher potential for adipogenic differentiation than for osteogenic and chondrogenic differentiation when compared with BM-MSCs[39,46,47].

## TYPES OF NANOFAT

### *Nanofat 2.0*

The unfiltered adipose tissue was initially called adult staminal cells by Lombardo *et al* [48] since they had higher proliferation capacity than the filtered cells. In 2017, Lo Furno *et al*[49] modified the method described by Tonnard *et al*[16] for nanofat, omitting the final filtration and squeezing the emulsified adipose sample through

nylon cloth. Lo Furno *et al*[49] named this product “nanofat 2.0”, which was highly rich in the stromal cell population and possessed an exponential proliferation capacity. Lo Furno *et al*[49] have demonstrated faster epithelization of the wound gap within 8 d by placing nanofat 2.0.

After harvesting the adipose tissue from the abdominal region under low negative pressure through a multiport 3 mm cannula with a hole diameter of 1 mm, the resultant lipoaspirate must be subjected to rinsing, filtration, and mechanical emulsification through serial passages between two 10-cc syringes connected by a Luer Lock connector. The resultant by-product after 30 passages is called “nanofat 2.0” (Figure 3) [49].

Nanofat 2.0 components stained highly positively for CD44, CD90, and CD105, which are the most specific immunohistochemical markers for mesenchymal stromal cells[27,49]. Moreover, they stained weakly positively for CD14, CD34, and CD45, which are the lineage markers for hematopoietic stem cells. Histological studies showed the loss of tissue integrity in nanofat 2.0 but revealed huge numbers of adipose-derived stromal cells and cellular debris[49]. Due to the availability of stromal cells and endothelial progenitor cells, nanofat 2.0 resulted in the healing of wounds and long-standing non-healing ulcers where a large volume of soft tissue augmentation was needed[48]. Lo Furno *et al*[49] demonstrated that nanofat 2.0 possessed increased stromal cell and endothelial precursor density and higher proliferative capacity than nanofat. Since nanofat 2.0 is subjected to less mechanical stress in preparation, the viability of the cellular content of the product could be enhanced compared to nanofat[48-51]. The modified nanofats are described in Table 1.

### **Vivo nanofat**

In 2018, Bi *et al*[52] formulated the preparation of nanofat with a combination of enzymatic disintegration and mechanical emulsification of adipose tissue and named this technique “Vivo nanofat”. The harvested lipoaspirate is rinsed with 1 mL of 0.2 mg/mL of collagenase I enzyme and the final volume is incubated at 37 °C for 15 min. The final concentrate is centrifuged at 300 G for 7 min and the supernatant fraction is filtered through a 0.6 mm sized cell strainer. The final effluent obtained is called Vivo nanofat. The cellular viability of adipocytes and stromal stem cells has been preserved to a great extent in Vivo nanofat[52]. Although the authors claim that the concentration of collagenase used (0.075%) was less than the amount used for adipose stromal cell separation, the effects of their concentration in the final derivative need further exploration.

---

## **DELIVERY OF NANOFAT**

---

The application and delivery of fat grafting to the recipient site are based on optimal vascularity for adipocyte survival. Nanofat can be delivered through micro-needling, intradermal, subcutaneous, and local infiltration depending on the need of the individual and the disease per se[53-55]. Delivering nanofat through small gauge cannulas reduces the recipient site morbidity, risk of bleeding, and poor graft uptake [56]. In fat grafting, the revascularization starts from the peripheral zones; hence, the center of the graft experiences a longer ischaemic time. Moreover, compared to a single injection, experts resort to repeated doses of fat grafting for enhanced benefits [56]. The fat grafting must be applied to the recipient site by withdrawing the cannula in a “fanning out” pattern.

The size of the cannula is the most important criterion to determine the fat application, graft uptake, and survival in the recipient site. However, there is a lack of consensus among studies on the ideal size to be utilized. While the conventional recommendation is to use a cannula less than 2.5 mm diameter to enhance the vitality of fat graft, but Erdim *et al*[59] did not note similar findings in their study on cell viability with differing needle gauge sizes[57-60].

---

## **APPLICATIONS OF NANOFAT**

---

Stem cells are an important component of regenerative medicine with increased significance and use in clinical applications. The newer concept of “Regenerative Surgery” has a great scope in augmenting and managing soft tissue defects and reconstructive procedures[61,62], of which adipose tissue-derived nanofat is gaining rapid attention.

Table 1 Modified nanofats

Type	Total volume of lipoaspirate	Procedure
Supercharged nanofat[24]	L + 80 mL	(1) First 80 mL lipoaspirate – Automatic filtration (120 µm filter) and centrifugation at 1300 rpm for 10 min in a closed system with 20 mL Luer lock syringes. The lower SVF was collected and further filtered to obtain the final 20 mL product; (2) Second 80 mL – Emulsification (30 passages) into two 10 mL Luer lock syringes; and (3) The SVF suspension obtained from the first lipoaspirate fraction should be mixed with the emulsified fat to form a supercharged nanofat
Evo modified nanofat[24]	L	(1) Slow centrifugation at 80 rpm for 3 min; and (2) Homogenization of emulsified fat through Luer lock system (20 passages)
Centrifuged modified nanofat [24]	L	(1) Direct centrifugation at 1300 rpm for 10 min; and (2) After discarding SVF, the concentrated aspirate of centrifuged fat should be emulsified by 30 passages through the Luer lock system

SVF: Stromal vascular fraction.

From the early 20th century, autologous fat grafting has gained much attention in the field of biocellular regenerative medicine and tissue engineering. Autologous fat grafting and the products of adipose tissue fragmentation have been used to restore the volume of soft tissue defects in the field of plastic surgery and soft tissue reconstruction. Considering the regenerative potential of adipose tissue, researchers are exploring to identify the key element responsible for its function. The adipose cells were considered the storehouse of progenitor cells and bioactive micromolecules[30]. By concentrating the progenitor cells within the adipose tissue complex, the regenerative capacity of the adipose-based products is enhanced to aid in their applications[21].

Nanofat grafting enhances neoangiogenesis without producing any visible scars and provides a favorable outcome in aesthetic medicine for breast, buttocks, and genital augmentation, facial rejuvenation, and facial volume augmentation[63-66]. The pre-clinical and clinical studies with the usage of nanofat have demonstrated the regenerative capacity of nanofat.

### Plastic surgery

Autologous fat transplantation or lipofillers remain the most suitable management modality available for breast reconstruction. Adipose tissue-derived nanofat can maintain natural breast shape and conceal the underlying prosthesis while augmenting breast size[67,68]. In gluteal augmentation, fat grafting can replace implant-based gluteal augmentation if the patient has adequate and available fat stores [69,70].

Nanofat injections can reduce the atrophic scars due to the presence of adipose tissue-derived stromal cells and avoid the need for surgical procedures[32]. The underlying mechanisms for scar retraction by nanofat are uncertain. Nanofat components can regenerate dermis and subcutaneous fatty tissues and enhance the dermo-epidermal junction. They regenerate by laying down adipose tissue-derived ECM, collagen deposition, and neoangiogenesis[71,72].

Zhang *et al*[73], in a preclinical study, emphasized the scar reduction in rabbit ears by decreasing the  $\alpha$ -SMA and collagen type I gene expression and enhancing collagen deposition with the usage of adipose-derived MSCs. Adipose tissue-derived MSCs restore collagen fibrillary organizations and downregulate the fibrosis of the scar tissue. Klinger *et al*[74] described that autologous fat grafting allows the skin to rejuvenate more softly and flexibly, and matches the color of neighboring skin which could be utilized to rejuvenate the texture and color of the skin of the scars present in joints, eyelids, face, and mouth.

**Burns:** With the advancements in tissue engineering, it is now possible to regenerate the burnt and scarred tissues with minimal scarring and donor site morbidity. Nanofat grafting beneath and within the substance of the scar improves the quality, integrity, and texture of the scar[75]. The histological evidence of fat grafting to scar demonstrates the hyperplasia of dermis and epidermis, vasculogenesis, and collagen deposition. Clinically, the fat grafted scar shows improved scar tone, texture, thickness, elasticity, flexibility, and color of the scar along with reduced scar size[76, 77].

### **Dermatology and aesthetic surgery**

The most common procedure for managing facial aesthetics is autologous fat transplantation. Though the transplanted adipose tissue gets absorbed easily, a few progenitor cells stimulate the process of regeneration. The cells present in nanofat in combination with platelet-rich fibrin (PRF) enhances the proliferation and adipogenic lineage differentiation.

Due to this combination treatment with nanofat and PRF, a trend towards the disappearance of wrinkles and improved facial contour and skin rejuvenation have been observed attributable to the autocrine and paracrine effects of stromal cells in nanofat and anti-aging properties of PRF[44,69,70]. This combination treatment enhances the long-term benefits and is being increasingly utilized in the restoration of facial contouring in the field of aesthetic and cosmetic medicine. The skin texture, elasticity, and moisture, and facial rejuvenation can be achieved with nanofat admixed with PRF[78].

In a pre-clinical trial, nanofat injection improved the thickness of the dermal layer and promoted angiogenesis in the photoaged skin of a nude mouse[79,80]. A wide range of improvements were seen in wrinkles, discolorations, and scars due to burns with nanofat applications[81-83]. Liang *et al*[84] emphasized that the combination treatment of nanofat and PRF improves facial depression when compared with hyaluronate filler.

Aesthetically, nanofat grafting is used for the correction of dark circles[85,86], malar bags[56], hollow eyes[86], and blepharoplasty[87]. Due to fat atrophy in the aging process, nanofat has emerged as a plausible technique for facial rejuvenation[88-90].

Apart from being a primary essential tool in revision rhinoplasty, nanofat is being increasingly used in primary rhinoplasty procedures also[91]. Nanofat is being used to correct slight skin irregularities which do not require cartilage grafting. Moreover, considering the cost of the revision rhinoplasty, nanofat grading is being employed frequently as a cost-effective procedure[92,93].

### **Orthopedics**

Due to the wide range of reconstructive and regenerative potentials of nanofat, the applications of nanofat can be extrapolated to orthopedic surgery. The mechanically emulsified adipose tissue can regenerate the degenerated and diseased tendon, ligaments, and articular cartilage[28].

Segreto *et al*[94] evaluated the role of a combination of nanofat grafting with autologous PRP in non-healing infected wounds. The application of nanofat with the micro-needling technique improved the delivery of cellular components into fibro-sclerotic tissues and enhanced the regeneration of soft tissue in chronic non-healing wounds. The addition of autologous PRP along with nanofat enhances the proliferative capacity and motility of adipose tissue-derived stromal cells[95,96].

Due to the multi-differentiation potential of adipose tissue, which is a component in nanofat grafting, it could be extrapolated for utilization in avascular necrosis of the femoral head, mild to moderate grades of osteoarthritis of knees, tendinopathies, and non-union of fractures.

---

## **COMPLICATIONS OF NANOFAT GRAFTING**

---

The lesser the fat graft is manipulated and the sooner it is injected, the higher the chances of its survival in the target site[97]. Minor complications related to the harvesting are due to the liposuction technique. The possible complications range from bruising, hematoma formation, donor-site pain, infection, contour irregularities, and damage to the underlying structures when the aspiration cannula enters peritoneal or muscular territories[98-103]. Breast augmentation with lipofilling was associated with complications such as fat necrosis, oil cyst formation, and calcifications when performed in large volumes into poorly vascularized areas. Cellulitis at the donor site [104], transient digital numbness[105], infections at both the recipient and harvest sites [106], and cyst formation[106,107] in 10% of hand rejuvenation patients, along with the common complications of fat grafting such as temporary dysaesthesia[106], fat necrosis[106,108], and reabsorption of the grafted fat[107] were also reported.

Facial rejuvenation by lipofilling involves complications related to the fat graft injections in "dangerous" areas of the face such as the glabella and nasolabial folds[88, 109]. Accidental intra-arterial injections may result in cerebral or ocular artery thrombosis resulting from the reflux of fat into the ophthalmic artery and the internal carotid artery[88,109]. To prevent such devastating complications, confirmation of the



absence of blood reflux into the syringe before injecting the graft is a necessary routine, along with a slow pace of injection at low pressure, and the use of a blunttip cannula [88,109].

---

## ETHICAL CONCERNS WITH NANOFAT GRAFTING

---

Therapeutic use of cellular products, including human cells, tissues, and tissue-based products, comes under the regulation of the Food and Drug Administration (FDA) in the United States and the European Medicines Agency in the European Union [110-112]. For a cellular product to be approved by the regulatory authorities, it should be minimally manipulated and intended for homologous use. Moreover, the entire procedure must be performed on the same day [112]. The main concern with this clause is to clarify the applications which account for the "homologous" use.

The FDA, while formulating these guidelines regarding fat-based therapeutic products, has considered only the adipocyte, not taking into account the potential constituents of the extracellular matrix such as multipotent stromal cells, pericytes, and endothelial precursor cells and restricted their approved usage only to the spectrum of disorders homologous to the utility of only the adipose lineage cellular component of the tissue complex. Appropriate homologous use of these heterogeneous populations with undesignated cellular capabilities needs to be clarified. Since nanofat is processed in a non-enzymatic method, it comes under the minimal manipulation norms of the FDA guidelines. Moreover, it is possible to procure, process, and place the cells in the target environment in a single surgical procedure, thereby reducing the need for additional procedures and the risk of contamination or genomic instability. The functional properties of extracellular matrix fragments, cellular debris, and blood cells in the heterogeneous composition of nanofat need to be defined. Consequently, problems of reproducibility and standardization methods may arise considering the subjectivity involved in the preparation process [113]. Hence, it is challenging to compare the efficacy of product protocols even when they are used for similar scenarios [114]. Therefore, increased efforts to optimize the preparation protocols with standardized methods of tissue manipulation for clinical purposes and analysis of grafting are needed.

---

## CONCLUSION

---

Nanofat, being a compact bundle of stem cells with regenerative and tissue remodeling potential, is a potential adipose tissue product in translational and regenerative medicine. Considering its wide reconstructive and regenerative potential, the applications of nanofat can be extrapolated to various disciplines. However, appropriate guidelines and preparation protocols for its optimal use have yet to be standardized for its vast range of clinical applications.

---

## REFERENCES

---

- 1 **Tsonis PA.** Regenerative biology: the emerging field of tissue repair and restoration. *Differentiation* 2002; **70**: 397-409 [PMID: 12366377 DOI: 10.1046/j.1432-0436.2002.700802.x]
- 2 **Mao AS, Mooney DJ.** Regenerative medicine: Current therapies and future directions. *Proc Natl Acad Sci U S A* 2015; **112**: 14452-14459 [PMID: 26598661 DOI: 10.1073/pnas.1508520112]
- 3 **Wehling M.** Translational medicine: science or wishful thinking? *J Transl Med* 2008; **6**: 31 [PMID: 18559092 DOI: 10.1186/1479-5876-6-31]
- 4 **Wehling M.** Translational medicine: can it really facilitate the transition of research "from bench to bedside"? *Eur J Clin Pharmacol* 2006; **62**: 91-95 [PMID: 16344921 DOI: 10.1007/s00228-005-0060-4]
- 5 **Nicoletti GF, De Francesco F, D'Andrea F, Ferraro GA.** Methods and procedures in adipose stem cells: state of the art and perspective for translation medicine. *J Cell Physiol* 2015; **230**: 489-495 [PMID: 25294367 DOI: 10.1002/jcp.24837]
- 6 **Astarita C, Arora CL, Trovato L.** Tissue regeneration: an overview from stem cells to micrografts. *J Int Med Res* 2020; **48**: 300060520914794 [PMID: 32536230 DOI: 10.1177/0300060520914794]
- 7 **Joo HJ, Kim JH, Hong SJ.** Adipose Tissue-Derived Stem Cells for Myocardial Regeneration. *Korean Circ J* 2017; **47**: 151-159 [PMID: 28382066 DOI: 10.4070/kcj.2016.0207]
- 8 **Kaminski DA, Randall TD.** Adaptive immunity and adipose tissue biology. *Trends Immunol* 2010; **31**: 384-390 [PMID: 20817556 DOI: 10.1016/j.it.2010.08.001]

- 9 **Enerbäck S.** Human brown adipose tissue. *Cell Metab* 2010; **11**: 248-252 [PMID: 20374955 DOI: 10.1016/j.cmet.2010.03.008]
- 10 **Chu DT,** Nguyen Thi Phuong T, Tien NLB, Tran DK, Minh LB, Thanh VV, Gia Anh P, Pham VH, Thi Nga V. Adipose Tissue Stem Cells for Therapy: An Update on the Progress of Isolation, Culture, Storage, and Clinical Application. *J Clin Med* 2019; **8** [PMID: 31247996 DOI: 10.3390/jcm8070917]
- 11 **Frese L,** Dijkman PE, Hoerstrup SP. Adipose Tissue-Derived Stem Cells in Regenerative Medicine. *Transfus Med Hemother* 2016; **43**: 268-274 [PMID: 27721702 DOI: 10.1159/000448180]
- 12 **Silva KR,** Baptista LS. Adipose-derived stromal/stem cells from different adipose depots in obesity development. *World J Stem Cells* 2019; **11**: 147-166 [PMID: 30949294 DOI: 10.4252/wjsc.v11.i3.147]
- 13 **Kamat P,** Frueh FS, McLuckie M, Sanchez-Macedo N, Wolint P, Lindenblatt N, Plock JA, Calcagni M, Buschmann J. Adipose tissue and the vascularization of biomaterials: Stem cells, microvascular fragments and nanofat-a review. *Cytotherapy* 2020; **22**: 400-411 [PMID: 32507607 DOI: 10.1016/j.jcyt.2020.03.433]
- 14 **Melief SM,** Zwaginga JJ, Fibbe WE, Roelofs H. Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. *Stem Cells Transl Med* 2013; **2**: 455-463 [PMID: 23694810 DOI: 10.5966/sctm.2012-0184]
- 15 **Beane OS,** Fonseca VC, Cooper LL, Koren G, Darling EM. Impact of aging on the regenerative properties of bone marrow-, muscle-, and adipose-derived mesenchymal stem/stromal cells. *PLoS One* 2014; **9**: e115963 [PMID: 25541697 DOI: 10.1371/journal.pone.0115963]
- 16 **Tonnard P,** Verpaele A, Peeters G, Hamdi M, Cornelissen M, Declercq H. Nanofat grafting: basic research and clinical applications. *Plast Reconstr Surg* 2013; **132**: 1017-1026 [PMID: 23783059 DOI: 10.1097/PRS.0b013e31829fe1b0]
- 17 **Ceccarelli S,** Pontecorvi P, Anastasiadou E, Napoli C, Marchese C. Immunomodulatory Effect of Adipose-Derived Stem Cells: The Cutting Edge of Clinical Application. *Front Cell Dev Biol* 2020; **8**: 236 [PMID: 32363193 DOI: 10.3389/fcell.2020.00236]
- 18 **Shaker RF,** Abdel Aal ARM, El Gazzar KMA, Abu Zahra FAK, Elshahat A. In Vitro Comparative Study of Emulsified Fat Grafts. *Eplasty* 2020; **20**: e1 [PMID: 32362987]
- 19 **Gentile P,** Orlandi A, Scioli MG, Di Pasquali C, Bocchini I, Cervelli V. Concise review: adipose-derived stromal vascular fraction cells and platelet-rich plasma: basic and clinical implications for tissue engineering therapies in regenerative surgery. *Stem Cells Transl Med* 2012; **1**: 230-236 [PMID: 23197782 DOI: 10.5966/sctm.2011-0054]
- 20 **Condé-Green A,** Kotamarti VS, Sherman LS, Keith JD, Lee ES, Granick MS, Rameshwar P. Shift toward Mechanical Isolation of Adipose-derived Stromal Vascular Fraction: Review of Upcoming Techniques. *Plast Reconstr Surg Glob Open* 2016; **4**: e1017 [PMID: 27757339 DOI: 10.1097/GOX.0000000000001017]
- 21 **Alexander RW.** Understanding Mechanical Emulsification (Nanofat) Versus Enzymatic Isolation of Tissue Stromal Vascular Fraction (tSVF) Cells from Adipose Tissue: Potential Uses in Biocellular Regenerative Medicine. *J Prolotherapy* 2016; **8**
- 22 **Memar O,** Nezamabadi A, Milani BY, Milani FY, Djalilian A. Nanofat grafting: basic research and clinical application. *Plast Reconstr Surg* 2014; **133**: 728e [PMID: 24776592 DOI: 10.1097/PRS.000000000000135]
- 23 **Grünherz L,** Sanchez-Macedo N, Frueh FS, McLuckie M, Lindenblatt N. Nanofat applications: from clinical esthetics to regenerative research: Potential applications of nanofat in tissue regeneration with a focus on wound healing and vascularization. *Curr Opin Biomed Eng* 2019; **10**: 174-180 [DOI: 10.1016/j.cobme.2019.07.002]
- 24 **Gentile P,** Scioli MG, Bielli A, Orlandi A, Cervelli V. Comparing different nanofat procedures on scars: role of the stromal vascular fraction and its clinical implications. *Regen Med* 2017; **12**: 939-952 [PMID: 29236575 DOI: 10.2217/rme-2017-0076]
- 25 **Young DA,** Christman KL. Injectable biomaterials for adipose tissue engineering. *Biomed Mater* 2012; **7**: 024104 [PMID: 22456805 DOI: 10.1088/1748-6041/7/2/024104]
- 26 **Sesé B,** Sanmartín JM, Ortega B, Matas-Palau A, Llull R. Nanofat Cell Aggregates: A Nearly Constitutive Stromal Cell Inoculum for Regenerative Site-Specific Therapies. *Plast Reconstr Surg* 2019; **144**: 1079-1088 [PMID: 31454336 DOI: 10.1097/PRS.0000000000006155]
- 27 **Cohen SR,** Tiryaki T, Womack HA, Canikyan S, Schlaudraff KU, Scheffan M. Cellular Optimization of Nanofat: Comparison of Two Nanofat Processing Devices in Terms of Cell Count and Viability. *Aesthet Surg J Open Forum* 2019; **1**: ojz028 [PMID: 33791619 DOI: 10.1093/asjof/ojz028]
- 28 **Tremolada C,** Colombo V, Ventura C. Adipose Tissue and Mesenchymal Stem Cells: State of the Art and Lipogems® Technology Development. *Curr Stem Cell Rep* 2016; **2**: 304-312 [PMID: 27547712 DOI: 10.1007/s40778-016-0053-5]
- 29 **Tamburino S,** Lombardo GA, Tarico MS, Perrotta RE. The Role of Nanofat Grafting in Vulvar Lichen Sclerosus: A Preliminary Report. *Arch Plast Surg* 2016; **43**: 93-95 [PMID: 26848453 DOI: 10.5999/aps.2016.43.1.93]
- 30 **Sarkanen JR,** Kaila V, Mannerström B, Rätty S, Kuokkanen H, Miettinen S, Ylikomi T. Human adipose tissue extract induces angiogenesis and adipogenesis in vitro. *Tissue Eng Part A* 2012; **18**: 17-25 [PMID: 21902602 DOI: 10.1089/ten.TEA.2010.0712]
- 31 **Gentile P,** Calabrese C, De Angelis B, Pizzicannella J, Kothari A, Garcovich S. Impact of the

- Different Preparation Methods to Obtain Human Adipose-Derived Stromal Vascular Fraction Cells (AD-SVFs) and Human Adipose-Derived Mesenchymal Stem Cells (AD-MSCs): Enzymatic Digestion Versus Mechanical Centrifugation. *Int J Mol Sci* 2019; **20** [PMID: 31684107 DOI: 10.3390/ijms20215471]
- 32 **Bhooshan LS**, Devi MG, Aniraj R, Binod P, Lekshmi M. Autologous emulsified fat injection for rejuvenation of scars: A prospective observational study. *Indian J Plast Surg* 2018; **51**: 77-83 [PMID: 29928084 DOI: 10.4103/ijps.IJPS\_86\_17]
- 33 **Evans GRD**, Widgeow AD. Stem cells and tissue engineering in plastic surgery: an update. *Plast Aesthetic Res* 2020; **7** [DOI: 10.20517/2347-9264.2019.53]
- 34 **Wang X**, Deng M, Yu Z, Cai Y, Liu W, Zhou G, Wang X, Cao Y, Li W, Zhang W. Cell-free fat extract accelerates diabetic wound healing in db/db mice. *Am J Transl Res* 2020; **12**: 4216-4227 [PMID: 32913499]
- 35 **Kemaloğlu CA**. Nanofat grafting under a split-thickness skin graft for problematic wound management. *Springerplus* 2016; **5**: 138 [PMID: 26933636 DOI: 10.1186/s40064-016-1808-2]
- 36 **Pu LL**. Mechanisms of Fat Graft Survival. *Ann Plast Surg* 2016; **77** Suppl 1: S84-S86 [PMID: 26808753 DOI: 10.1097/SAP.0000000000000730]
- 37 **Doornaert M**, Colle J, De Maere E, Declercq H, Blondeel P. Autologous fat grafting: Latest insights. *Ann Med Surg (Lond)* 2019; **37**: 47-53 [PMID: 30622707 DOI: 10.1016/j.amsu.2018.10.016]
- 38 **Zheng H**, Yu Z, Deng M, Cai Y, Wang X, Xu Y, Zhang L, Zhang W, Li W. Fat extract improves fat graft survival *via* proangiogenic, anti-apoptotic and pro-proliferative activities. *Stem Cell Res Ther* 2019; **10**: 174 [PMID: 31196213 DOI: 10.1186/s13287-019-1290-1]
- 39 **Mohamed-Ahmed S**, Frisstad I, Lie SA, Suliman S, Mustafa K, Vindenes H, Idris SB. Adipose-derived and bone marrow mesenchymal stem cells: a donor-matched comparison. *Stem Cell Res Ther* 2018; **9**: 168 [PMID: 29921311 DOI: 10.1186/s13287-018-0914-1]
- 40 **Park SH**, Sim WY, Min BH, Yang SS, Khademhosseini A, Kaplan DL. Chip-based comparison of the osteogenesis of human bone marrow- and adipose tissue-derived mesenchymal stem cells under mechanical stimulation. *PLoS One* 2012; **7**: e46689 [PMID: 23029565 DOI: 10.1371/journal.pone.0046689]
- 41 **Niemeyer P**, Kornacker M, Mehlhorn A, Seckinger A, Vohrer J, Schmal H, Kasten P, Eckstein V, Südkamp NP, Krause U. Comparison of immunological properties of bone marrow stromal cells and adipose tissue-derived stem cells before and after osteogenic differentiation in vitro. *Tissue Eng* 2007; **13**: 111-121 [PMID: 17518585 DOI: 10.1089/ten.2006.0114]
- 42 **Guneta V**, Tan NS, Chan SK, Tanavde V, Lim TC, Wong TC, Choong C. Comparative study of adipose-derived stem cells and bone marrow-derived stem cells in similar microenvironmental conditions. *Exp Cell Res* 2016; **348**: 155-164 [PMID: 27658569 DOI: 10.1016/j.yexcr.2016.09.012]
- 43 **Strioga M**, Viswanathan S, Darinskas A, Slaby O, Michalek J. Same or not the same? *vs* **21**: 2724-2752 [PMID: 22468918 DOI: 10.1089/scd.2011.0722]
- 44 **Hennig T**, Lorenz H, Thiel A, Goetzke K, Dickhut A, Geiger F, Richter W. Reduced chondrogenic potential of adipose tissue derived stromal cells correlates with an altered TGFbeta receptor and BMP profile and is overcome by BMP-6. *J Cell Physiol* 2007; **211**: 682-691 [PMID: 17238135 DOI: 10.1002/jcp.20977]
- 45 **Stromps JP**, Paul NE, Rath B, Nourbakhsh M, Bernhagen J, Pallua N. Chondrogenic differentiation of human adipose-derived stem cells: a new path in articular cartilage defect management? *Biomed Res Int* 2014; **2014**: 740926 [PMID: 25019085 DOI: 10.1155/2014/740926]
- 46 **Pachón-Peña G**, Yu G, Tucker A, Wu X, Vendrell J, Bunnell BA, Gimble JM. Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct immunophenotypic profiles. *J Cell Physiol* 2011; **226**: 843-851 [PMID: 20857424 DOI: 10.1002/jcp.22408]
- 47 **Sakaguchi Y**, Sekiya I, Yagishita K, Muneta T. Comparison of human stem cells derived from various mesenchymal tissues: superiority of synovium as a cell source. *Arthritis Rheum* 2005; **52**: 2521-2529 [PMID: 16052568 DOI: 10.1002/art.21212]
- 48 **Lombardo GAG**, Tamburino S. The Unfiltered Nanofat: A Great Source of Staminal Cells. *Ann Plast Surg* 2019; **83**: 488 [PMID: 31524748 DOI: 10.1097/SAP.0000000000001958]
- 49 **Lo Furno D**, Tamburino S, Mannino G, Gili E, Lombardo G, Tarico MS, Vancheri C, Giuffrida R, Perrotta RE. Nanofat 2.0: experimental evidence for a fat grafting rich in mesenchymal stem cells. *Physiol Res* 2017; **66**: 663-671 [PMID: 28406706 DOI: 10.33549/physiolres.933451]
- 50 **Huang R**, Jiao H, Fan J, Liu L, Tian J, Gan C, Yang Z, Zhang T, Zeng Y, Su Z. Nanofat Injection for the Treatment of Depressed Facial Scars. *Aesthetic Plast Surg* 2021; **45**: 1762-1771 [PMID: 33635346 DOI: 10.1007/s00266-021-02178-7]
- 51 **Bianchi F**, Maioli M, Leonardi E, Olivi E, Pasquinelli G, Valente S, Mendez AJ, Ricordi C, Raffaini M, Tremolada C, Ventura C. A new nonenzymatic method and device to obtain a fat tissue derivative highly enriched in pericyte-like elements by mild mechanical forces from human lipoaspirates. *Cell Transplant* 2013; **22**: 2063-2077 [PMID: 23051701 DOI: 10.3727/096368912X657855]
- 52 **Bi HS**, Zhang C, Nie FF, Pan BL, Xiao E. Basic and Clinical Evidence of an Alternative Method to Produce Vivo Nanofat. *Chin Med J (Engl)* 2018; **131**: 588-593 [PMID: 29483394 DOI: 10.4103/0366-6999.226074]
- 53 **Menkes S**, Luca M, Soldati G, Polla L. Subcutaneous Injections of Nanofat Adipose-derived Stem

- Cell Grafting in Facial Rejuvenation. *Plast Reconstr Surg Glob Open* 2020; **8**: e2550 [PMID: 32095390 DOI: 10.1097/GOX.0000000000002550]
- 54 **Righesso R**, Piccinini PS, Uebel CO. A Combined Approach for Fast Nanofat Microneedling. *J Cutan Aesthet Surg* 2021; **14**: 248-255 [PMID: 34566373 DOI: 10.4103/JCAS.JCAS\_142\_20]
- 55 **Kakagia D**, Pallua N. Autologous fat grafting: in search of the optimal technique. *Surg Innov* 2014; **21**: 327-336 [PMID: 24480787 DOI: 10.1177/1553350613518846]
- 56 **Simonacci F**, Bertozzi N, Grieco MP, Grignaffini E, Raposio E. Procedure, applications, and outcomes of autologous fat grafting. *Ann Med Surg (Lond)* 2017; **20**: 49-60 [PMID: 28702187 DOI: 10.1016/j.amsu.2017.06.059]
- 57 **Tong Y**, Liu P, Wang Y, Geng C, Han X, Ma J, Li F, Cai L. The Effect of Liposuction Cannula Diameter on Fat Retention-Based on a Rheological Simulation. *Plast Reconstr Surg Glob Open* 2018; **6**: e2021 [PMID: 30881807 DOI: 10.1097/GOX.0000000000002021]
- 58 **Gause TM 2nd**, Kling RE, Sivak WN, Marra KG, Rubin JP, Kokai LE. Particle size in fat graft retention: A review on the impact of harvesting technique in lipofilling surgical outcomes. *Adipocyte* 2014; **3**: 273-279 [PMID: 26317051 DOI: 10.4161/21623945.2014.957987]
- 59 **Erdim M**, Tezel E, Numanoglu A, Sav A. The effects of the size of liposuction cannula on adipocyte survival and the optimum temperature for fat graft storage: an experimental study. *J Plast Reconstr Aesthet Surg* 2009; **62**: 1210-1214 [PMID: 18572007 DOI: 10.1016/j.bjps.2008.03.016]
- 60 **Vazquez OA**, Markowitz MI, Becker H. Fat Graft Size: Relationship Between Cannula and Needle Diameters. *Cureus* 2020; **12**: e7598 [PMID: 32399332 DOI: 10.7759/cureus.7598]
- 61 **Orlando G**, Wood KJ, De Coppi P, Baptista PM, Binder KW, Bitar KN, Breuer C, Burnett L, Christ G, Farney A, Figliuzzi M, Holmes JH 4th, Koch K, Macchiarini P, Mirmalek Sani SH, Opara E, Remuzzi A, Rogers J, Saul JM, Seliktar D, Shapira-Schweitzer K, Smith T, Solomon D, Van Dyke M, Yoo JJ, Zhang Y, Atala A, Stratta RJ, Soker S. Regenerative medicine as applied to general surgery. *Ann Surg* 2012; **255**: 867-880 [PMID: 22330032 DOI: 10.1097/SLA.0b013e318243a4db]
- 62 **Orlando G**, Wood KJ, Stratta RJ, Yoo JJ, Atala A, Soker S. Regenerative medicine and organ transplantation: past, present, and future. *Transplantation* 2011; **91**: 1310-1317 [PMID: 21505379 DOI: 10.1097/TP.0b013e318219ebb5]
- 63 **O'Neill RC**, Abu-Ghname A, Davis MJ, Chamata E, Rammos CK, Winocour SJ. The Role of Fat Grafting in Buttock Augmentation. *Semin Plast Surg* 2020; **34**: 38-46 [PMID: 32071578 DOI: 10.1055/s-0039-3401038]
- 64 **Sun W**, Li T, Yao H, Kang L, Dong F. Effects of concentrated growth factor and nanofat on aging skin of nude mice induced by D-galactose. *Physiol Res* 2021; **70**: 425-435 [PMID: 33982585 DOI: 10.33549/physiolres.934640]
- 65 **Coleman SR**, Katzel EB. Fat Grafting for Facial Filling and Regeneration. *Clin Plast Surg* 2015; **42**: 289-300, vii [PMID: 26116934 DOI: 10.1016/j.cps.2015.04.001]
- 66 **Abu-Ghname A**, Perdanasari AT, Reece EM. Principles and Applications of Fat Grafting in Plastic Surgery. *Semin Plast Surg* 2019; **33**: 147-154 [PMID: 31384229 DOI: 10.1055/s-0039-1693438]
- 67 **Pu LL**, Yoshimura K, Coleman SR. Future Perspectives of Fat Grafting. *Clin Plast Surg* 2015; **42**: 389-394, ix [PMID: 26116945 DOI: 10.1016/j.cps.2015.03.007]
- 68 **Pu LL**, Yoshimura K, Coleman SR. Fat grafting: current concept, clinical application, and regenerative potential, part 1. *Clin Plast Surg* 2015; **42**: ix-ix [PMID: 25827569 DOI: 10.1016/j.cps.2015.02.001]
- 69 **Ho Quoc C**, Mojallal A, Delay E. [Esthetic gluteal remodeling by fat grafting]. *Ann Chir Plast Esthet* 2013; **58**: 194-200 [PMID: 23219187 DOI: 10.1016/j.anplas.2012.10.014]
- 70 **Ho Quoc C**, Mojallal A. [Semiology for gluteal remodeling by lipofilling]. *Ann Chir Plast Esthet* 2012; **57**: 580-586 [PMID: 23084603 DOI: 10.1016/j.anplas.2012.09.002]
- 71 **Sharma S**, Muthu S, Jeyaraman M, Ranjan R, Jha SK. Translational products of adipose tissue-derived mesenchymal stem cells: Bench to bedside applications. *World J Stem Cells* 2021; In press
- 72 **Riyat H**, Touil LL, Briggs M, Shokrollahi K. Autologous fat grafting for scars, healing and pain: a review. *Scars Burn Heal* 2017; **3**: 2059513117728200 [PMID: 29799544 DOI: 10.1177/2059513117728200]
- 73 **Zhang Q**, Liu LN, Yong Q, Deng JC, Cao WG. Intralesional injection of adipose-derived stem cells reduces hypertrophic scarring in a rabbit ear model. *Stem Cell Res Ther* 2015; **6**: 145 [PMID: 26282394 DOI: 10.1186/s13287-015-0133-y]
- 74 **Klinger M**, Caviggioli F, Klinger FM, Giannasi S, Bandi V, Banzatti B, Forcellini D, Maione L, Catania B, Vinci V. Autologous fat graft in scar treatment. *J Craniofac Surg* 2013; **24**: 1610-1615 [PMID: 24036737 DOI: 10.1097/SCS.0b013e3182a24548]
- 75 **Bruno A**, Delli Santi G, Fasciani L, Cempanari M, Palombo P. Burn scar lipofilling: immunohistochemical and clinical outcomes. *J Craniofac Surg* 2013; **24**: 1806-1814 [PMID: 24036785 DOI: 10.1097/SCS.0b013e3182a148b9]
- 76 **Caviggioli F**, Klinger FM, Vinci V, Cornegliani G, Klinger M. Treatment of chronic posttraumatic leg injury using autologous fat graft. *Case Rep Med* 2012; **2012**: 648683 [PMID: 23319957 DOI: 10.1155/2012/648683]
- 77 **Al-Hayder S**, Gramkow C, Trojahn Kølle SF. Use of autologous fat grafting for the correction of burn scar contracture in the hand: a case report. *Case Reports Plast Surg Hand Surg* 2017; **4**: 81-83 [PMID: 28971111 DOI: 10.1080/23320885.2017.1369883]
- 78 **Wei H**, Gu SX, Liang YD, Liang ZJ, Chen H, Zhu MG, Xu FT, He N, Wei XJ, Li HM. Nanofat-derived stem cells with platelet-rich fibrin improve facial contour remodeling and skin rejuvenation

- after autologous structural fat transplantation. *Oncotarget* 2017; **8**: 68542-68556 [PMID: 28978136 DOI: 10.18632/oncotarget.19721]
- 79 **Xu P**, Yu Q, Huang H, Zhang WJ, Li W. Nanofat Increases Dermis Thickness and Neovascularization in Photoaged Nude Mouse Skin. *Aesthetic Plast Surg* 2018; **42**: 343-351 [PMID: 29380024 DOI: 10.1007/s00266-018-1091-4]
- 80 **Xu Y**, Deng M, Cai Y, Zheng H, Wang X, Yu Z, Zhang W, Li W. Cell-Free Fat Extract Increases Dermal Thickness by Enhancing Angiogenesis and Extracellular Matrix Production in Nude Mice. *Aesthet Surg J* 2020; **40**: 904-913 [PMID: 31679030 DOI: 10.1093/asj/sjz306]
- 81 **Jan SN**, Bashir MM, Khan FA, Hidayat Z, Ansari HH, Sohail M, Bajwa AB, Shami HB, Hanif A, Aziz F, Choudhery MS. Unfiltered Nanofat Injections Rejuvenate Postburn Scars of Face. *Ann Plast Surg* 2019; **82**: 28-33 [PMID: 30285990 DOI: 10.1097/SAP.0000000000001631]
- 82 **Gu Z**, Li Y, Li H. Use of Condensed Nanofat Combined With Fat Grafts to Treat Atrophic Scars. *JAMA Facial Plast Surg* 2018; **20**: 128-135 [PMID: 28975248 DOI: 10.1001/jamafacial.2017.1329]
- 83 **Pallua N**, Baroncini A, Alharbi Z, Stromps JP. Improvement of facial scar appearance and microcirculation by autologous lipofilling. *J Plast Reconstr Aesthet Surg* 2014; **67**: 1033-1037 [PMID: 24909626 DOI: 10.1016/j.bjps.2014.04.030]
- 84 **Liang ZJ**, Lu X, Li DQ, Liang YD, Zhu DD, Wu FX, Yi XL, He N, Huang YQ, Tang C, Li HM. Precise Intradermal Injection of Nanofat-Derived Stromal Cells Combined with Platelet-Rich Fibrin Improves the Efficacy of Facial Skin Rejuvenation. *Cell Physiol Biochem* 2018; **47**: 316-329 [PMID: 29768259 DOI: 10.1159/000489809]
- 85 **Ziade G**, Karam D. Emulsified fat and nanofat for the treatment of dark circles. *Dermatol Ther* 2020; **33**: e14100 [PMID: 32725706 DOI: 10.1111/dth.14100]
- 86 **Oh DS**, Kim DH, Roh TS, Yun IS, Kim YS. Correction of Dark Coloration of the Lower Eyelid Skin with Nanofat Grafting. *Arch Aesthetic Plast Surg* 2014; **20**: 92-96 [DOI: 10.14730/aaps.2014.20.2.92]
- 87 **Kranendonk S**, Obagi S. Autologous fat transfer for periorbital rejuvenation: indications, technique, and complications. *Dermatol Surg* 2007; **33**: 572-578 [PMID: 17451580 DOI: 10.1111/j.1524-4725.2007.33116.x]
- 88 **Boureaux E**, Chaput B, Bannani S, Herlin C, De Runz A, Carloni R, Mortemousque B, Mouriaux F, Watier E, Bertheuil N. Eyelid fat grafting: Indications, operative technique and complications; a systematic review. *J Craniomaxillofac Surg* 2016; **44**: 374-380 [PMID: 26880013 DOI: 10.1016/j.jcms.2015.12.013]
- 89 **Le TP**, Peckinpugh J, Naficy S, Amadi AJ. Effect of autologous fat injection on lower eyelid position. *Ophthalmic Plast Reconstr Surg* 2014; **30**: 504-507 [PMID: 24814272 DOI: 10.1097/IOP.0000000000000160]
- 90 **Rihani J**. Microfat and Nanofat: When and Where These Treatments Work. *Facial Plast Surg Clin North Am* 2019; **27**: 321-330 [PMID: 31280846 DOI: 10.1016/j.fsc.2019.03.004]
- 91 **Bayat M**, Bahrami N, Mesgari H. Rhinoplasty with Fillers and Fat Grafting. *Oral Maxillofac Surg Clin North Am* 2021; **33**: 83-110 [PMID: 33246548 DOI: 10.1016/j.coms.2020.09.004]
- 92 **Erol OO**. Microfat Grafting in Nasal Surgery. *Aesthet Surg J* 2014; **34**: 671-686 [PMID: 24754966 DOI: 10.1177/1090820X14529444]
- 93 **Kao WP**, Lin YN, Lin TY, Huang YH, Chou CK, Takahashi H, Shieh TY, Chang KP, Lee SS, Lai CS, Lin SD, Lin TM. Microautologous Fat Transplantation for Primary Augmentation Rhinoplasty: Long-Term Monitoring of 198 Asian Patients. *Aesthet Surg J* 2016; **36**: 648-656 [PMID: 26764261 DOI: 10.1093/asj/sjv253]
- 94 **Segreto F**, Marangi GF, Nobile C, Alessandri-Bonetti M, Gregorj C, Cerbone V, Gratteri M, Caldaria E, Tirindelli MC, Persichetti P. Use of platelet-rich plasma and modified nanofat grafting in infected ulcers: Technical refinements to improve regenerative and antimicrobial potential. *Arch Plast Surg* 2020; **47**: 217-222 [PMID: 32453929 DOI: 10.5999/aps.2019.01571]
- 95 **Cervelli V**, Gentile P, Scioli MG, Grimaldi M, Casciani CU, Spagnoli LG, Orlandi A. Application of platelet-rich plasma in plastic surgery: clinical and *in vitro* evaluation. *Tissue Eng Part C Methods* 2009; **15**: 625-634 [PMID: 19231923 DOI: 10.1089/ten.TEC.2008.0518]
- 96 **D'Esposito V**, Passaretti F, Perruolo G, Ambrosio MR, Valentino R, Oriente F, Raciti GA, Nigro C, Miele C, Sammartino G, Beguinot F, Formisano P. Platelet-Rich Plasma Increases Growth and Motility of Adipose Tissue-Derived Mesenchymal Stem Cells and Controls Adipocyte Secretory Function. *J Cell Biochem* 2015; **116**: 2408-2418 [PMID: 26012576 DOI: 10.1002/jcb.25235]
- 97 **Shih L**, Davis MJ, Winocour SJ. The Science of Fat Grafting. *Semin Plast Surg* 2020; **34**: 5-10 [PMID: 32071573 DOI: 10.1055/s-0039-3402073]
- 98 **Hamza A**, Lohsiriwat V, Rietjens M. Lipofilling in breast cancer surgery. *Gland Surg* 2013; **2**: 7-14 [PMID: 25083450 DOI: 10.3978/j.issn.2227-684X.2013.02.03]
- 99 **Shukla L**, Yuan Y, Shayan R, Greening DW, Karnezis T. Fat Therapeutics: The Clinical Capacity of Adipose-Derived Stem Cells and Exosomes for Human Disease and Tissue Regeneration. *Front Pharmacol* 2020; **11**: 158 [PMID: 32194404 DOI: 10.3389/fphar.2020.00158]
- 100 **Gornitsky J**, Viezel-Mathieu A, Alnaif N, Azzi AJ, Gilardino MS. A systematic review of the effectiveness and complications of fat grafting in the facial region. *JPRAS Open* 2019; **19**: 87-97 [PMID: 32158860 DOI: 10.1016/j.jptra.2018.12.004]
- 101 **Yang F**, Ji Z, Peng L, Fu T, Liu K, Dou W, Li J, Li Y, Long Y, Zhang W. Efficacy, safety and complications of autologous fat grafting to the eyelids and periorbital area: A systematic review and meta-analysis. *PLoS One* 2021; **16**: e0248505 [PMID: 33793573 DOI: 10.1371/journal.pone.0248505]

- 10.1371/journal.pone.0248505]
- 102 **Ilouz YG**, Sterodimas A. Autologous fat transplantation to the breast: a personal technique with 25 years of experience. *Aesthetic Plast Surg* 2009; **33**: 706-715 [PMID: 19495856 DOI: 10.1007/s00266-009-9377-1]
- 103 **Chan CW**, McCulley SJ, Macmillan RD. Autologous fat transfer--a review of the literature with a focus on breast cancer surgery. *J Plast Reconstr Aesthet Surg* 2008; **61**: 1438-1448 [PMID: 18848513 DOI: 10.1016/j.bjps.2008.08.006]
- 104 **Hoang D**, Orgel MI, Kulber DA. Hand Rejuvenation: A Comprehensive Review of Fat Grafting. *J Hand Surg Am* 2016; **41**: 639-644 [PMID: 27113709 DOI: 10.1016/j.jhsa.2016.03.006]
- 105 **De Jongh F**, Pouwels S, Tan LT. Autologous Fat Grafting for the Treatment of a Painful Neuroma of the Hand: A Case Report and Review of Literature. *Cureus* 2020; **12**: e10381 [PMID: 33062502 DOI: 10.7759/cureus.10381]
- 106 **Butterwick KJ**. Rejuvenation of the aging hand. *Dermatol Clin* 2005; **23**: 515-527, vii [PMID: 16039431 DOI: 10.1016/j.det.2005.04.007]
- 107 **Fantozzi F**. Hand rejuvenation with fat grafting: A 12-year single-surgeon experience. *Eur J Plast Surg* 2017; **40**: 457-464 [PMID: 28989238 DOI: 10.1007/s00238-017-1337-4]
- 108 **Vara AD**, Miki RA, Alfonso DT, Cardoso R. Hand fat grafting complicated by abscess: A case of a bilateral hand abscess from bilateral hand fat grafting. *Hand (N Y)* 2013; **8**: 348-351 [PMID: 24426947 DOI: 10.1007/s11552-013-9508-7]
- 109 **Park SH**, Sun HJ, Choi KS. Sudden unilateral visual loss after autologous fat injection into the nasolabial fold. *Clin Ophthalmol* 2008; **2**: 679-683 [PMID: 19668775]
- 110 **Turner LG**. Federal Regulatory Oversight of US Clinics Marketing Adipose-Derived Autologous Stem Cell Interventions: Insights From 3 New FDA Draft Guidance Documents. *Mayo Clin Proc* 2015; **90**: 567-571 [PMID: 25939934 DOI: 10.1016/j.mayocp.2015.02.003]
- 111 **Raposo E**, Ciliberti R. Clinical use of adipose-derived stem cells: European legislative issues. *Ann Med Surg (Lond)* 2017; **24**: 61-64 [PMID: 29204274 DOI: 10.1016/j.amsu.2017.11.002]
- 112 **Marks P**, Gottlieb S. Balancing Safety and Innovation for Cell-Based Regenerative Medicine. *N Engl J Med* 2018; **378**: 954-959 [PMID: 29514023 DOI: 10.1056/NEJMsr1715626]
- 113 **Debnath T**, Chelluri LK. Standardization and quality assessment for clinical grade mesenchymal stem cells from human adipose tissue. *Hematol Transfus Cell Ther* 2019; **41**: 7-16 [PMID: 30793099 DOI: 10.1016/j.htct.2018.05.001]
- 114 **Gimble JM**, Bunnell BA, Chiu ES, Guilak F. Concise review: Adipose-derived stromal vascular fraction cells and stem cells: let's not get lost in translation. *Stem Cells* 2011; **29**: 749-754 [PMID: 21433220 DOI: 10.1002/stem.629]



Published by **Baishideng Publishing Group Inc**  
7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)

**Help Desk:** <https://www.f6publishing.com/helpdesk>

<https://www.wjgnet.com>

